MEDNYSEMiscellaneous Food Preparations & Kindred ProductsFiscal year ends December 31

MEDIFAST INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$12.03+0.15 (+1.26%)

Close on Oct 19, 2026

Market cap: $133.95M
P/E (TTM): –
Dividend yield: 0.00%

MEDIFAST INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	386	602	1,072	1,599	1,526	935	714	501	302	275	273	285	324	319	298	258	170
Cost of Revenue	111	158	296	458	398	237	177	121	74	69	71	76	83	83	74	65	45
Gross Profit	275	445	776	1,140	1,128	698	537	380	228	206	201	209	241	236	224	192	124
Research & Development	4.30	4.60	4.60	4.50	4.40	2.80	2.70	2.20	1.50	2.00	1.80	1.30	–	–	–	–	–
Selling, General & Admin	289	442	649	956	911	564	446	311	188	179	173	179	202	209	197	161	106
Advertising Expenses	7.50	14	3.40	1.70	1.60	4.40	5.30	6.00	7.70	9.40	15	17	21	26	27	23	–
Operating Income	-14	2.88	126	185	216	134	91	69	40	27	29	30	38	27	27	32	18
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	0.01	0.06	0.09	0.10	0.15
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.42	0.39	0.16
Other Non-Operating Income	8.57	0.91	2.40	-0.75	-0.11	0.11	1.32	1.49	0.69	0.26	0.99	1.45	0.63	1.22	0.30	0.05	-0.07
Merger & Restructuring Charges	13	13	–	12	–	–	–	–	–	1.34	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	6.08	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	-4.09	0.15	0	0	–	–	0.00	-0.08	0.12	0.53	0.77	0.07	0.00	-0.21	-0.21	-0.08
Gain (Loss) on Sale of Assets	-1.37	-0.09	-1.17	-2.13	0.00	-0.21	-0.02	-0.05	-0.09	0.01	-0.08	0.03	-0.39	-0.10	0	0	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.01	–
Pretax Income	-5.64	3.79	129	184	216	134	92	71	40	27	30	32	39	28	28	32	18
Income Tax Expense	13	1.70	29	40	52	31	14	15	13	9.29	10	11	12	9.91	9.14	12	7.07
Income from Continuing Operations	–	–	–	–	–	–	–	56	28	18	20	21	27	18	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	0.49	-7.85	-3.17	-2.57	–	–	–
Net Income	-19	2.09	99	144	164	103	78	56	28	18	20	13	24	16	19	20	11
EPS (Basic)(per share)	-1.70	0.19	9.13	12.82	14.01	8.74	6.62	4.67	2.32	1.51	1.68	1.04	1.74	1.16	1.33	1.39	0.84
EPS (Diluted)(per share)	-1.70	0.19	9.10	12.73	13.89	8.68	6.43	4.62	2.29	1.49	1.66	1.03	1.73	1.16	1.31	1.35	0.77
Shares Outstanding (Basic, Weighted)(shares)	11	11	11	11	12	12	12	12	12	12	12	13	14	14	14	14	14
Shares Outstanding (Diluted, Weighted)(shares)	11	11	11	11	12	12	12	12	12	12	12	13	14	14	14	15	15
Dividend per Share(per share)	0.00	0.00	4.95	6.56	5.68	4.52	3.38	2.19	1.44	1.07	0.25	0.00	0.00	–	–	–	–
EBITDA	0.03	16	140	196	223	138	96	73	44	32	36	38	46	36	36	37	24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.2%
Operating margin: -6.2%
Net margin: -8.1%
Return on equity, FY2025: -9.1%

Financial strength

Current ratio: 4.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 173.0%

Valuation

P/E ratio: –
Price to sales: 0.42
Price to book: 0.68
Dividend yield: 0.00%